Groups Hope New Congress Will Pass Bipartisan Bills Centered On Rare Diseases

By Gabrielle Wanneh / November 22, 2022 at 2:30 PM
Rare disease advocacy groups hope the new Congress will prioritize investment in the development of rare disease treatments by passing bills that restore and reinforce seven-year exclusivity for drugs being developed for specific rare conditions, require regular reporting to improve the approval process of orphan drug designation and ensure patient input is counted throughout the development process. With Republicans set to control the House and Democrats to maintain control of the Senate, and new committee leaders yet to be formally...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.